Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Cash And Cash Equivalents : ¥238.7 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Anhui Wanbang Pharmaceutical Technology Co Cash And Cash Equivalents?

Anhui Wanbang Pharmaceutical Technology Co's quarterly cash and cash equivalents declined from Sep. 2023 (¥1,051.68 Mil) to Dec. 2023 (¥253.50 Mil) but then stayed the same from Dec. 2023 (¥253.50 Mil) to Mar. 2024 (¥238.75 Mil).

Anhui Wanbang Pharmaceutical Technology Co's annual cash and cash equivalents increased from Dec. 2021 (¥161.47 Mil) to Dec. 2022 (¥186.16 Mil) and increased from Dec. 2022 (¥186.16 Mil) to Dec. 2023 (¥253.50 Mil).

Anhui Wanbang Pharmaceutical Technology Co Cash And Cash Equivalents Historical Data

The historical data trend for Anhui Wanbang Pharmaceutical Technology Co's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anhui Wanbang Pharmaceutical Technology Co Cash And Cash Equivalents Chart

Anhui Wanbang Pharmaceutical Technology Co Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

Get a 7-Day Free Trial

5.64

119.87

161.47

186.16

253.50

Anhui Wanbang Pharmaceutical Technology Co Quarterly Data
	Dec18	Dec19	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial									-	170.56	1,051.68	253.50	238.75

Anhui Wanbang Pharmaceutical Technology Co Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Anhui Wanbang Pharmaceutical Technology Co Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Anhui Wanbang Pharmaceutical Technology Co's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Anhui Wanbang Pharmaceutical Technology Co Ltd (SZSE:301520) » Definitions » Cash And Cash Equivalents

Traded in Other Exchanges

N/A

Address

southwest corner of the intersection of Mingzhu Avenue and Huolongdi Road, Building 1, Anhui Wanbang Pharmaceutical, High-tech Zone, Anhui, Hefei, CHN, 230000

Website

http://www.ahwbyy.cn

Anhui Wanbang Pharmaceutical Technology Co Ltd is a one-stop CRO service platform that engages in the entire process from pharmaceutical development to clinical research of innovative drugs, improved new drugs and generic drugs. It aims to provide drug research and development and clinical trials for drug launch, including pharmaceutical research, clinical services, biological sample analysis and testing, SMO services and data statistics and analysis.

Anhui Wanbang Pharmaceutical Technology Co (SZSE:301520) Headlines

No Headlines